ESTRO 36 Abstract Book

S737 ESTRO 36 2017 _______________________________________________________________________________________________

irradiated vertebrae (43.9% of esophagitis if more than 5 vertebrae are irradiated versus 25.3% if less than 6 vertebrae are irradiated). Conclusion The incidence of esophagitis after palliative CRT of cervico-thoracic spinal metastases led to considering static or dynamic Intensity Modulated Radiation Therapy (IMRT) to reduce the dose to organ at risk (esophagus). IMRT could be primarily beneficial if palliative radiotherapy concerns vertebrae between C5 and T4 and if it affects more than 5 vertebrae. EP-1392 Prognostic factors for survival in patients with bone metastases P.M. Samper Ots 1 , M. Hernandez Miguel 1 , E. Amaya Escobar 1 , M.D. De las Peñas Cabrera 1 1 Hospital Rey Juan Carlos, Servicio de Oncologia Radioterapica, Mostoles - Madrid, Spain Purpose or Objective To analyze the prognostic factors for survival in patients Retrospective analysis of 104 patients referred for treatment of bone metastases, median age was 59 years, 69 males (66.3%). The most common primary tumors were: lung 36 cases (34.6%), prostate 24 (23.1%) and breast 13 (12.6%). The means time diagnosis of bone metastases was 14.55 ± 2 months. 85 patients were treated with 3DRT (81.7%), 9 SBRT (8.7%) and 10 no treatment (9.6%). The study was approved by the Ethics Committee for Clinical Research (CEIC) and meets the standards of data protection. For statistical analysis SPSS version 22.0 was used. Results 70 patients (67.3%) died with a median survival of 14.4 months after the diagnosis of bone metastases. Survival according to the treatment was: 3DRT 13.73 ± 21.3 months, SBRT 20.7 ± 12.0 months and without RT 10.48 ± 10.7 months (p <0.001). The median survival after end of radiotherapy was 19.4 ± 5.66 months. Prognostic factors for survival were: primary tumor controlled versus uncontrolled 45.3 ± 15.4 versus 7.64 ± 1.09 months (p = 0.001), metastases in other organs 15.23 ± 5.2 versus not 22 ± 4.7 months (p = 0.04), lymph node metastasis 13 ± 5.06 versus not 18 ± 4.3 months (p = 0.007), liver metastases 6.42 ± 1.52 versus not 24.44 ± 7.75 months (p = 0.028), ECOG 0 (49.5 ± 17.1), 1 (7.49 ± 1.38), 2 (8.78 ± 1.97) and 3 (3.88 ± 1) p = 0.003. The primary diagnosis: lung 5.68 ± 1.25 months, breast 59.81 ± 21.12 months, prostate 18.85 ± 5.2 months (p = 0.013). In patients with lung cáncer, the histology was a prognostic factor: epidermoid 2.65 ± 0.9 months, adenocarcinoma 7.69 ± 1.8 months and small cell 1.92 ± 1.32 months (p = 0.009). The time to diagnosis of bone metastases was not prognostic factor for survival. Conclusion In patients with bone metastases, the best prognosis are breast cáncer, primary controlled, no other metastases, SBRT and ECOG 0. EP-1393 Prognostic factors for survival in patients with brain metastases P.M. Samper Ots 1 , M. Hernandez Miguel 1 , E. Amaya Escobar 1 , M.D. De las Peñas Cabrera 1 1 Hospital Rey Juan Carlos, servicio de oncologia Radioterapia, Mostoles - Madrid, Spain Purpose or Objective To analyze the prognostic factors for survival in patients with bone metastases. Material and Methods

tumors were: lung 56 cases (64.4%), breast 12 (13.8 %) and colorectal 9 (10.3%). The means time diagnosis of brain metastases was 16.3 ± 35.36 months. 63 patients were treated with holocraneal 3DRT (72.4%), 5 holocraneal and boost (5.7%), 6 Stereotactic fracctionated radiotherapy (SFR) (6.8%) and 13 no treatment (14.9%). The study was approved by the Ethics Committee for Clinical Research (CEIC) and meets the standards of data protection. For statistical analysis SPSS version 22.0 was used. Results 73 patients (83.9%) died with a median survival of 7.66 ± 0.96 months after the diagnosis of brain metastases. Survival according to the treatment was: holocraneal 6.84 ± 0.97 months, holocraneal and boost 13.06 ± 6.04 months, SFR 7.38 ± 1.5 months and without RT 6.38 ± 2.6 months (p <0.519). The median survival after end of radiotherapy was 6.47 ± 0.98 months. The time to diagnosis of brain metastases, the situation of the primary, metastases in other organs, number of brain metastases, surgery of metastases, radiosurgery were not prognostic factors for survival. Prognostic factors for survival were: ECOG 0 (8.99 ± 1.43 months), 1 (8.05 ± 2.26 months), 2 (2.78 ± 0.64 months) and 3 (1.24 ± 0.94 months) p = 0.000. Not completing radiotherapy 0.24 ± 0.12 versus 7.27 ± 1.07 months (p = 0.000). The primary diagnosis: lung 6.96 ± 1.34 months, breast 5.38 ± 1.47 months, colorectal 5.72 ± 2.19 months (p = 0.016). The histology: adenocarcinoma 7.93 ± 1.99 months, infiltrating ductal 5.36 ± 1.47 months, small cell 4.94 ± 1.07 months, and epidermoid 3.08 ± 1.0 months, (p = 0.004). In patients with breast cancer estrogen and progesterona receptors, negative 1.54 ± 1.3 months and positive 9.8 ± 1.03 months In patients with brain metastases, the best prognosis are lung cancer, adenocarcinoma, ECOG 0, and in breast cancer are positive estrogen and progesterona receptors. EP-1394 Prognostic factor for palliative radiotherapy of bone metastases in good performance-status patients Y. Hamamoto 1 , S. Taguchi 2 , T. Manabe 2 , H. Kanzaki 1 , K. Nagasaki 1 , N. Takata 1 , T. Mochizuki 1 1 Ehime University, Radiology, Toon-city, Japan 2 Saiseikai Imabari Hospital, Radiology, Imabari-city, Japan Purpose or Objective Performance status is well-known prognostic factor for patients received palliative care. Regarding patients with good performance status, prognostic factors after palliative intent radiation therapy (PIRT) were investigated. Material and Methods Between Dec. 2009 and Mar. 2014, 148 patients received initial PIRT in our institution. Of these, 100 patients were able to be followed up until death or for more than six months. Among these 100 patients, 63 patients (age, 58- 89, median 69; male/female=45/18) were in good performance status (PS 0-1), and were reviewed in this study. Survival time was calculated from the initiation of initial PIRT. Assessed factors were age (<75 vs. >75), sex, primary sites (breast vs. other organs), sites of initial PIRT (bone/soft-tissue/lymph-nodes vs. other organs), and administration of chemotherapy before PIRT (yes vs. no). Univariate analysis was performed by log-rank test and multivariate analysis was performed by Cox proportional hazard model. Results Regarding all 63 patients, median survival time was seven months and the 1-year overall survival rate was 34%. On univariate analysis, irradiate sites was the only statistically significant factor for survival after PIRT (p=0.0159). Irradiate sites was the statistically significant factor also on multivariate analysis (p=0.0179). The 1-year overall survival rate of the patients who received PIRT to (p=0.025). Conclusion

with brain metastases. Material and Methods

Retrospective analysis of 87 patients referred for treatment of brain metastases, median age was 62.3 ± 13 years, 56 males (64.4 %). The most common primary